SEC Info - ReShape Lifesciences Inc. - ‘10-Q’ for 9/30/20

Quarterly Report — Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    388K 
 2: EX-10.1     Material Contract                                   HTML    354K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
12: R1          Document and Entity Information                     HTML     48K 
13: R2          Condensed Consolidated Balance Sheets               HTML     97K 
14: R3          Condensed Consolidated Balance Sheets               HTML     26K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     66K 
                and Comprehensive Loss                                           
16: R5          Condensed Consolidated Statements of Stockholders'  HTML    107K 
                Equity                                                           
17: R6          Condensed Consolidated Statements of Cash Flows     HTML    109K 
18: R7          Organization and Basis of Presentation              HTML     30K 
19: R8          Summary of Significant Accounting Policies          HTML     39K 
20: R9          Fair Value Measurements                             HTML     83K 
21: R10         Net Loss per Share                                  HTML     45K 
22: R11         Balance Sheet Details                               HTML     69K 
23: R12         Loan                                                HTML     24K 
24: R13         Stock-Based Compensation                            HTML     89K 
25: R14         Stockholders' Equity                                HTML     37K 
26: R15         Income Taxes                                        HTML     22K 
27: R16         Commitments and Contingencies                       HTML     45K 
28: R17         Variable Interest Entity                            HTML     22K 
29: R18         Summary of Significant Accounting Policies          HTML     59K 
                (Policies)                                                       
30: R19         Fair Value Measurements (Tables)                    HTML     83K 
31: R20         Net Loss per Share (Tables)                         HTML     47K 
32: R21         Balance Sheet Details (Tables)                      HTML     72K 
33: R22         Stock-Based Compensation (Tables)                   HTML     93K 
34: R23         Stockholders' Equity (Tables)                       HTML     23K 
35: R24         Commitments and Contingencies (Tables)              HTML     32K 
36: R25         Organization and Basis of Presentation -            HTML     38K 
                Additional Information (Detail)                                  
37: R26         Summary of Significant Accounting Policies -        HTML     23K 
                Narrative (Details)                                              
38: R27         Fair Value Measurements - Schedule of Assets and    HTML     49K 
                Liabilities Measured at Fair Value on Recurring                  
                Basis (Details)                                                  
39: R28         Fair Value Measurements - Schedule of Fair Value    HTML     32K 
                Assumptions (Details)                                            
40: R29         Fair Value Measurements - Schedule of Liabilities   HTML     26K 
                Measured at Fair Value (Details)                                 
41: R30         Net Loss per Share - Schedule of Computation of     HTML     32K 
                Basic and Diluted Net Loss Per Share of Common                   
                Stock (Details)                                                  
42: R31         Net Loss per Share - Schedule of Anti-Dilutive      HTML     24K 
                Common Stock Equivalents Excluded from the                       
                Calculation of Diluted Net Loss Per Share                        
                (Details)                                                        
43: R32         Balance Sheet Details - Schedule of Inventory       HTML     27K 
                (Details)                                                        
44: R33         Balance Sheet Details - Narrative (Details)         HTML     28K 
45: R34         Balance Sheet Details - Schedule of Other Current   HTML     28K 
                Assets (Details)                                                 
46: R35         Balance Sheet Details - Schedule of Property and    HTML     45K 
                Equipment, Net (Details)                                         
47: R36         Balance Sheet Details - Schedule of Other Current   HTML     35K 
                Liabilities (Details)                                            
48: R37         Loan - Additional Information (Details)             HTML     24K 
49: R38         Stock-Based Compensation - Additional Information   HTML     36K 
                (Details)                                                        
50: R39         Stock-Based Compensation - Summary of Stock-Based   HTML     28K 
                Compensation (Details)                                           
51: R40         Stock-Based Compensation - Summary of Stock Option  HTML     70K 
                Transactions (Details)                                           
52: R41         Stock-Based Compensation - Summary of Restricted    HTML     58K 
                Stock Awards (Details)                                           
53: R42         Stockholders' Equity - Additional Information       HTML     70K 
                (Details)                                                        
54: R43         Stockholders' Equity - Schedule of Common Stock     HTML     28K 
                Reserved for Future Issuance (Details)                           
55: R44         Commitments and Contingencies - Additional          HTML     51K 
                Information (Details)                                            
56: R45         Commitments and Contingencies - Schedule of Future  HTML     50K 
                Noncancelable Minimum Payment Obligations Under                  
                Operating Lease (Details)                                        
57: R46         Variable Interest Entity (Details)                  HTML     23K 
59: XML         IDEA XML File -- Filing Summary                      XML    103K 
58: EXCEL       IDEA Workbook of Financial Reports                  XLSX     71K 
 6: EX-101.INS  XBRL Instance -- obln-20200930                       XML   1.22M 
 8: EX-101.CAL  XBRL Calculations -- obln-20200930_cal               XML    174K 
 9: EX-101.DEF  XBRL Definitions -- obln-20200930_def                XML    327K 
10: EX-101.LAB  XBRL Labels -- obln-20200930_lab                     XML   1.15M 
11: EX-101.PRE  XBRL Presentations -- obln-20200930_pre              XML    647K 
 7: EX-101.SCH  XBRL Schema -- obln-20200930                         XSD    112K 
60: ZIP         XBRL Zipped Folder -- 0001427570-20-000062-xbrl      Zip    149K

‘R17’ — Variable Interest Entity

This is an IDEA Financial Report. [ Alternative Formats ]

Variable Interest Entity	9 Months Ended
Variable Interest Entity	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entity	Variable Interest Entity In conjunction with the Company’s strategic focus to open weight loss treatment centers to provide medical services to patients who wish to lose weight through the Obalon balloon system, the Company entered into a consulting agreement with a lead doctor to open the first treatment center and oversee the treatment center’s activities. The treatment center was opened in September 2019 as a professional corporation (“PC”) in the State of California and, as a result of state regulatory requirements, may not be owned by a corporation. The Company fully funds all the activities of the treatment center and no financial contributions are made by the lead doctor. In addition, the Company is authorized and expected to provide daily oversight of the activities of the center, with the exception of directly providing medical services. As the PC’s equity investment at risk is not sufficient to permit the entity to finance its activities without subordinated financial support, the PC is considered a variable interest entity. Although the Company does not own any equity interest in the PC, the Company holds the controlling financial interest as the sole funding source for the entity and through the ability to provide daily oversight. Therefore, the Company was determined to be the primary beneficiary of the PC and consolidated the PC’s balances and activity within its condensed consolidated financial statements. For the nine months ended September 30, 2020, the PC recognized $0.3 million of deferred revenue associated with prepaid services at the treatment center, which is fully presented in the condensed consolidated balance sheet of the Company at September 30, 2020.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	11/6/20	8-K
For Period end:	9/30/20
		List all Filings

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/09/21  ReShape Lifesciences Inc.         S-4/A                 89:13M                                    Toppan Merrill/FA
 3/30/21  ReShape Lifesciences Inc.         S-4                   25:18M                                    Toppan Merrill/FA
 3/12/21  ReShape Lifesciences Inc.         10-K       12/31/20   83:8.4M                                   Toppan Merrill Bridge/FA
 2/03/21  ReShape Lifesciences Inc.         S-8         2/03/21    3:211K                                   Toppan Merrill Bridge/FA

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/14/20  ReShape Lifesciences Inc.         8-K:1,3,9   8/14/20    3:203K
 7/24/19  ReShape Lifesciences Inc.         8-K:3,5,8,9 7/23/19    3:71K
 6/14/18  ReShape Lifesciences Inc.         8-K:5,9     6/14/18    2:53K
 9/26/16  ReShape Lifesciences Inc.         S-1/A                 17:4M                                     Donnelley … Solutions/FA

↑Top

Filing Submission 0001427570-20-000062 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

ReShape Lifesciences Inc. – ‘10-Q’ for 9/30/20 – ‘R17’

On: Friday, 11/6/20, at 4:31pm ET · For: 9/30/20 · Accession #: 1427570-20-62 · File #: 1-37897

Previous ‘10-Q’: ‘10-Q’ on 7/30/20 for 6/30/20 · Next: ‘10-Q’ on 5/12/21 for 3/31/21 · Latest: ‘10-Q’ on 11/9/23 for 9/30/23 · 8 References:

Quarterly Report — Form 10-Q
Filing Table of Contents

‘R17’ — Variable Interest Entity

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

4 Previous Filings that this Filing References

ReShape Lifesciences Inc. – ‘10-Q’ for 9/30/20 – ‘R17’

On: Friday, 11/6/20, at 4:31pm ET · For: 9/30/20 · Accession #: 1427570-20-62 · File #: 1-37897

Quarterly Report — Form 10-QFiling Table of Contents

‘R17’ — Variable Interest Entity

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

4 Previous Filings that this Filing References

Quarterly Report — Form 10-Q
Filing Table of Contents